RNA-Binding Protein Switch Could Sensitize Deadly Pancreatic Cancer to Radiation

Pancreatic ductal adenocarcinoma, the most common and most lethal form of pancreatic cancer, has long frustrated oncologists with its stubborn resistance to radiation therapy. Now a study published in the Journal of Translational Medicine offers a detailed molecular explanation for that resistance, and potentially a way around it. A research team based at the First Medical Center of PLA General Hospital in Beijing reports that a protein called PAFAH1B1, whose levels are suppressed in pancreatic tumors, acts as a gatekeeper of radiosensitivity. When the researchers restored PAFAH1B1 in radiation-resistant pancreatic cancer cells and in mouse tumors, the cells became markedly more vulnerable to iodine-125 radioactive seed therapy, a form of brachytherapy in which tiny encapsulated radiation sources are implanted directly into or near a tumor to deliver a continuous, localized dose.

The clinical significance of the finding rests on a grim statistical reality. Pancreatic cancer carries one of the lowest five-year survival rates of any malignancy worldwide, and radioresistance remains one of the principal obstacles to effective treatment. In the new study, the team first examined PAFAH1B1 expression in patient tissue using immunohistochemistry, western blotting, and quantitative reverse transcription PCR. They found that the protein was consistently downregulated in pancreatic ductal adenocarcinoma, and that low levels correlated with unfavorable prognosis and poorer response to radiotherapy. In other words, patients whose tumors had less of this protein fared worse when radiation entered the treatment plan, a pattern that immediately suggested PAFAH1B1 might be doing something biologically important beyond its established biochemical role.

PAFAH1B1, formally known as platelet activating factor acetylhydrolase 1b regulatory subunit 1, is not an obscure molecule. It has well-documented functions in cellular physiology, but its connection to radiation response in pancreatic cancer had not been mapped. To probe that connection, the researchers took a practical experimental route: they established two radiation-resistant pancreatic cancer cell lines, derived from the commonly used BxPC-3 and PANC-1 lines, by exposing them to conditions that selected for survival under repeated radiation challenge. They also grew xenograft tumors in mice using the radiation-resistant PANC-1 cells, creating a living model in which the effectiveness of iodine-125 particle therapy could be tested under controlled conditions.

The results were striking. When the team forced PAFAH1B1 overexpression in the radiation-resistant cells, the cells lost much of their defensive capacity. Cell viability and proliferation, measured with CCK-8 assays and colony formation tests, dropped sharply after radiation exposure compared with resistant cells that lacked the extra PAFAH1B1. Flow cytometry revealed shifts in apoptosis as well. Crucially, the same effect appeared in the xenograft model: tumors engineered to overexpress PAFAH1B1 responded better to iodine-125 particle treatment than their resistant counterparts. This demonstrated that the protein’s influence was not an artifact of cell culture but persisted in a whole-animal context, where tumor architecture, blood supply, and immune factors all complicate the picture.

The mechanism behind this sensitization turned out to be ferroptosis, an iron-dependent form of regulated cell death that has attracted intense interest in cancer biology over the past decade. Unlike apoptosis, ferroptosis kills cells through the catastrophic oxidation of lipids in their membranes. It depends on the accumulation of reactive oxygen species and on phospholipids containing polyunsaturated fatty acids, which are particularly vulnerable to peroxidation. When lipid peroxides build up faster than the cell’s antioxidant systems can neutralize them, the membrane disintegrates and the cell dies. The researchers evaluated ferroptosis directly using commercial assay kits and BODIPY 581/591 C11 staining, a fluorescent probe whose signal shifts when it inserts into oxidized lipids, providing a visual and quantitative readout of lipid peroxidation within living cells.

What the staining and assays showed was that PAFAH1B1 overexpression potentiated the ferroptotic response to radiation. Radiation alone damages cells in many ways, including through DNA breaks and free radical generation, but resistant pancreatic cancer cells had apparently learned to buffer or repair that damage. Restoring PAFAH1B1 tipped the balance back toward death by amplifying the lipid peroxidation cascade that defines ferroptosis. This reframes radioresistance in pancreatic cancer not simply as a matter of DNA repair capacity, but as a failure of the tumor to undergo this oxidative form of cell death, a failure that can potentially be corrected by manipulating a single regulatory axis.

That regulatory axis is where the study becomes technically intricate. The researchers asked how PAFAH1B1 levels are controlled in the first place, and the answer lies in the untranslated region at the tail end of its messenger RNA, the 3′ untranslated region or 3′-UTR. This segment of RNA does not code for protein but serves as a landing platform for regulatory molecules. Two microRNAs, miR-421 and miR-301a-3p, bind to this region and suppress PAFAH1B1 production, a classic post-transcriptional silencing mechanism. The team confirmed these interactions using luciferase reporter assays, in which the PAFAH1B1 3′-UTR is fused to a light-producing enzyme so that any change in binding translates into a measurable change in luminescence, and by RNA immunoprecipitation, which physically pulls down protein-RNA complexes to verify who is bound to whom inside cells.

Enter PUM2, or Pumilio 2, an RNA-binding protein with a very different agenda. Rather than silencing the message, PUM2 binds to the same 3′-UTR and stabilizes it, boosting PAFAH1B1 expression. The competitive element is the key insight: PUM2 and the two microRNAs compete for overlapping or adjacent binding sites on the same RNA molecule. When PUM2 occupies the region, it crowds out miR-421 and miR-301a-3p, shielding the transcript from degradation and allowing more PAFAH1B1 protein to be made. The researchers used actinomycin D chase experiments, which block new RNA synthesis so that the decay rate of existing transcripts can be measured, to demonstrate that PUM2 binding extends the lifespan of the PAFAH1B1 message. Through this tug-of-war on a single stretch of RNA, PUM2 effectively overrides the microRNA brake.

The final piece of the puzzle was confirming that PUM2’s pro-ferroptotic effect depends entirely on PAFAH1B1. When the team manipulated PUM2 levels, they found that it promoted radiation-induced ferroptosis, but only when PAFAH1B1 was present to be upregulated. Knock down PAFAH1B1 and PUM2 loses its leverage; restore it and the sensitization returns. This establishes a clean causal chain: PUM2 outcompetes inhibitory microRNAs on the PAFAH1B1 3′-UTR, PAFAH1B1 protein accumulates, radiation-induced lipid peroxidation proceeds unchecked, ferroptosis executes the cell, and iodine-125 particle therapy works as intended. Disrupt any link in that chain, as pancreatic tumors apparently do by downregulating PAFAH1B1, and radioresistance follows.

The translational implications are considerable, though the road from mechanism to medicine is long. The study, supported by the Beijing Nova Program and conducted under ethics approval in accordance with the Declaration of Helsinki and ARRIVE animal guidelines, suggests that strategies to elevate PAFAH1B1, whether by enhancing PUM2 activity, blocking miR-421 and miR-301a-3p, or delivering PAFAH1B1 directly, could convert radiation-resistant pancreatic tumors into treatable ones. It also positions ferroptosis induction as a companion target for iodine-125 seed therapy, which is already used clinically for localized tumor control. For a disease where five-year survival remains the lowest among major cancers, any molecular handle that makes radiation bite harder is worth pursuing, and this PUM2-PAFAH1B1-ferroptosis pathway now offers one of the most mechanistically complete maps of pancreatic cancer radioresistance published to date.

Subject of Research: PUM2-mediated PAFAH1B1 stabilization and ferroptosis in overcoming radioresistance to iodine-125 particle therapy in pancreatic ductal adenocarcinoma

Article Title: PAFAH1B1 stabilization, through PUM2-mediated competitive binding with miRNAs on its’ 3’-UTR, takes active actions on ferroptosis to overcome the radioresistance to 125I radioactive particles of pancreatic ductal adenocarcinoma

Article References: Bi, Y., Shen, W., Ma, C., Tang, A., Jian, K., Jiang, L., Liu, Y., & Min, M. (2026). PAFAH1B1 stabilization, through PUM2-mediated competitive binding with miRNAs on its’ 3’-UTR, takes active actions on ferroptosis to overcome the radioresistance to 125I radioactive particles of pancreatic ductal adenocarcinoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08948-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08948-8

Keywords: PAFAH1B1, PUM2, ferroptosis, pancreatic ductal adenocarcinoma, radioresistance, iodine-125, microRNA, miR-421, miR-301a-3p, radiosensitivity, RNA-binding protein, 3'-UTR